Literature DB >> 8547129

Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases.

R Torra1, J Bladé, A Cases, J López-Pedret, E Montserrat, C Rozman, L Revert.   

Abstract

From January 1982 to December 1993, 30 patients with multiple myeloma (MM) required haemodialysis (HD) at our institution. The subgroup of 20 patients who survived more than 2 months on HD is the subject of this study. Four patients were already on HD, due to previous nephropathy, when MM was diagnosed. 13 patients presented with acute renal failure and were on dialysis from the time of diagnosis. The remaining three cases developed renal failure later in the course of the disease. The objective response rate was 40% (8/20). Only two patients could discontinue HD (one had a late partial recovery and one received a kidney graft). Mean hospitalization per year was 19.3 d. The subgroup of patients who survived < 1 year spent a mean of 38.3 d in hospital. Whereas in the subgroup with a survival > 1 year mean hospitalization days was 9.6 (P < 0.001). The median survival was 20 months and six patients survived for > 3 years. In summary, patients with MM and severe renal failure who survive the first 2 months on dialysis have an objective response rate to chemotherapy of 40% and a median survival of almost 2 years, with 30% long-term survivors.

Entities:  

Mesh:

Year:  1995        PMID: 8547129     DOI: 10.1111/j.1365-2141.1995.tb05400.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  29 in total

1.  Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

Authors:  Colin A Hutchison; Paul Cockwell; Stephanie Stringer; Arthur Bradwell; Mark Cook; Morie A Gertz; Angela Dispenzieri; Jeffrey L Winters; Shaji Kumar; S Vincent Rajkumar; Robert A Kyle; Nelson Leung
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 2.  Novel approaches for reducing free light chains in patients with myeloma kidney.

Authors:  Colin A Hutchison; Joan Bladé; Paul Cockwell; Mark Cook; Mark Drayson; Jean-Paul Fermand; Efstathios Kastritis; Robert Kyle; Nelson Leung; Sonia Pasquali; Christopher Winearls
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

3.  The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study.

Authors:  Berdien E Oortgiesen; Roshna Azad; Marc H Hemmelder; Robby E Kibbelaar; Nic J G M Veeger; Joost C de Vries; Eric N van Roon; Mels Hoogendoorn
Journal:  Haematologica       Date:  2018-03-15       Impact factor: 9.941

Review 4.  Current Trends of Renal Impairment in Multiple Myeloma.

Authors:  Punit Yadav; Mark Cook; Paul Cockwell
Journal:  Kidney Dis (Basel)       Date:  2016-02-03

5.  The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies.

Authors:  Richard Fish; Jennifer Pinney; Poorva Jain; Clara Addison; Chris Jones; Satish Jayawardene; John Booth; Alexander J Howie; Tareck Ghonemy; Shahista Rajabali; David Roberts; Lucy White; Sofia Khan; Matthew Morgan; Paul Cockwell; Colin A Hutchison
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-22       Impact factor: 8.237

6.  Determination of intrarenal resistance index (RI) in patients with multiple myeloma.

Authors:  U Schiemann; H C Kaiser; M Götzberger; R Schmidmaier; F Bantle; C Straka
Journal:  Eur J Med Res       Date:  2010-05-18       Impact factor: 2.175

Review 7.  Kidney disease associated with plasma cell dyscrasias.

Authors:  Eliot C Heher; Nelson B Goes; Thomas R Spitzer; Noopur S Raje; Benjamin D Humphreys; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2010-05-12       Impact factor: 22.113

8.  Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure.

Authors:  I Breitkreutz; C Heiss; A Perne; J Beimler; D Jäger; G Egerer; A D Ho; K Neben; M Zeier; H Goldschmidt; M S Raab
Journal:  Bone Marrow Transplant       Date:  2014-08-04       Impact factor: 5.483

Review 9.  Kidney disease and multiple myeloma.

Authors:  Eliot C Heher; Helmut G Rennke; Jacob P Laubach; Paul G Richardson
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-18       Impact factor: 8.237

10.  Pulmonary hypertension complicating multiple myeloma.

Authors:  Udhay Krishnan; Tomer M Mark; Ruben Niesvizky; Irina Sobol
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.